541 completed, 273 recruiting, 193 terminated, 193 unknown. 648 Phase 2, 592 Phase 1, 138 Phase 3, 112 Not applicable, 23 Early Phase 1.
Follow Acute Myeloid Leukemia: new trials by email Literature Review of Acute Myeloid Leukemia trials Research Report on Acute Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Universal CAR-T Cells Targeting AML CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells - Acute Myeloid Leukemia | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-08-27 |
| Universal 4SCAR7U Targeting CD7-positive Malignancies Universal CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-08-26 |
| Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML Decitabine, Venetoclax, Axatilimab - Acute Myeloid Leukemia, TP53 Gene Mutation | Phase 1 | Not yet recruiting | Northside Hospital, Inc. | 32 | 2027-01-31 | 2026-10-16 |
| Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 122 | 2027-01-15 | 2026-10-07 |
| Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Biopsy - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 244 | 2027-01-15 | 2026-10-20 |
| Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) Azacitidine, Bone Marrow Aspiration and Biopsy, Cytarabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 184 | 2027-01-04 | 2026-10-01 |
| Feasibility and Efficiency Study for the Implementation of a New Screening Method for Patients With Acute Myeloid Leukemia, in Laboratory Practice Bone marrow or peripheral blood withdrawal for test comparison - Acute Myeloid Leukemia, Acute Myeloid Leukemia, Adult | Not applicable | Not yet recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 75 | 2027-01-01 | 2026-10-09 |
| GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors VTRU200 - Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Vitruviae | 108 | 2027-01-01 | 2026-08-06 |
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| Prevention of Oral Mucositis in Adults in With Hematologic Malignancy Aloe Vera Mouthwash, Standard of Care - Acute Leukemia, Acute Myeloid Leukemia | Not applicable | Not yet recruiting | Wake Forest University Health Sciences | 206 | 2027-01-01 | 2026-10-22 |
| Multi-CAR T Cell Therapy for Acute Myeloid Leukemia Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 10 | 2026-12-31 | 2026-08-26 |
| Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2026-12-31 | 2026-08-26 |
| Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies Ossium HPC, Marrow, Standard of care living donor - Haplo Related, Standard of care living donor - Mismatched Unrelated - Hematologic Malignancy, Acute Leukemia | Not applicable | Not yet recruiting | Ossium Health, Inc. | 300 | 2026-12-01 | 2026-09-10 |
| Menin-Inhibitor Targeted Maintenance in AML Revumenib, Placebo - Relapsed Adult AML, Stem Cell Transplant Complications | Phase 2 | Not yet recruiting | Center for International Blood and Marrow Transplant Research | 146 | 2026-12-01 | 2026-06-22 |
| Geriatric Assessment-Guided Treatment Selection in Older Adults With Acute Myeloid Leukemia GA-directed treatment regimens - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | University of Rochester | 120 | 2026-12-01 | 2026-07-29 |
| A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant Maintenance Therapy, No intervention - Myeloid Disorders, Myelodysplastic Syndromes | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 450 | 2026-12-01 | 2026-10-13 |
| Digital Patient-Reported Assessment in Older Adults With Acute Leukemia Digital Patient-Reported Assessment Pathway - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Not applicable | Not yet recruiting | Fundación para la Investigación Biosanitaria del Principado de Asturias | 20 | 2026-12-01 | 2026-10-07 |
| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | BeOne Medicines | 30 | 2026-12-01 | 2026-10-26 |
| Prophylactic DLI-X for Leukemia Relapse After HCT Exercise Mobilized Prophylactic DLI, Standard Prophylactic DLI - Acute Lymphoid Leukemia, Acute Myeloid Leukemia | Phase 1 | Not yet recruiting | University of Arizona | 180 | 2026-11-30 | 2026-10-22 |
| Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 132 | 2026-11-27 | 2026-09-09 |
Showing 20 of 1484. Sign in to see all of them.
Leukemia, Myeloid, Acute (1484) · Myelodysplastic Syndromes (405) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (228) · Leukemia (127) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (110) · Leukemia, Myelomonocytic, Chronic (89) · Lymphoma, Non-Hodgkin (82) · Recurrence (81) · Myeloproliferative Disorders (72) · Multiple Myeloma (69) · Leukemia, Lymphocytic, Chronic, B-Cell (66) · Hematologic Neoplasms (63) · Leukemia, Biphenotypic, Acute (60) · Hodgkin Disease (56) · Neoplasms (45)
Hemic and Lymphatic Diseases (1484) · Neoplasms by Histologic Type (1481) · Leukemia, Myeloid (1466) · Hematologic Diseases (1464) · Neoplasms (1439) · Leukemia (1357) · Bone Marrow Diseases (476) · Pathological Conditions, Signs and Symptoms (328) · Pathologic Processes (324) · Immune System Diseases (311) · Immunoproliferative Disorders (306) · Lymphoproliferative Disorders (304) · Lymphatic Diseases (300) · Disease Attributes (296) · Leukemia, Lymphoid (263)
Cytarabine (237) · Azacitidine (187) · venetoclax (171) · fludarabine (104) · Decitabine (93) · Cyclophosphamide (85) · Daunorubicin (85) · Idarubicin (70) · Specimen Handling (62) · Granulocyte Colony-Stimulating Factor (53) · fludarabine phosphate (52) · Busulfan (50) · Whole-Body Irradiation (45) · Biopsy (44) · Mycophenolic Acid (44)
M.D. Anderson Cancer Center (67) · National Cancer Institute (NCI) (44) · The First Affiliated Hospital of Soochow University (32) · Fred Hutchinson Cancer Center (29) · City of Hope Medical Center (28) · Masonic Cancer Center, University of Minnesota (22) · Massachusetts General Hospital (17) · AbbVie (16) · Institute of Hematology & Blood Diseases Hospital, China (16) · Novartis Pharmaceuticals (16) · St. Jude Children's Research Hospital (16) · Gruppo Italiano Malattie EMatologiche dell'Adulto (15) · Dana-Farber Cancer Institute (14) · Washington University School of Medicine (14) · Assistance Publique - Hôpitaux de Paris (13)
United States (777) · China (214) · France (160) · Germany (120) · Canada (96) · Italy (94) · Spain (83) · United Kingdom (61) · Australia (58) · South Korea (48) · Belgium (36) · Poland (32) · Taiwan (32) · Austria (31) · Netherlands (31)
Courtney DiNardo, MD (5) · Farhad Ravandi-Kashani, MD (5) · Jianxiang Wang, MD (5) · Qifa Liu (5) · Anna Halpern (4) · Areej El-Jawahri, MD (4) · Brenda Sandmaier (4) · Daniel Pollyea, MD (4)
PMID 33394722, PMID 36184192, PMID 38429079, PMID 42013378, PMID 19602710, PMID 20625116, PMID 21343560, PMID 21459791, PMID 21459795, PMID 22649106, PMID 22965967, PMID 23071272, PMID 23248249, PMID 23749683, PMID 24816240, PMID 28054442, PMID 29702001, PMID 29859851, PMID 30062662, PMID 30337300, PMID 31171508, PMID 32499241, PMID 32786187, PMID 33741715, PMID 34255353, PMID 34267079, PMID 34614506, PMID 35704787, PMID 36064577, PMID 37093350, PMID 37703506, PMID 39368878, PMID 39892383, PMID 40073835, PMID 40513054, PMID 40973764, PMID 41621809, PMID 41796974, PMID 42419338, PMID 10231138, PMID 10583235, PMID 11015443, PMID 11313690, PMID 12242449, PMID 12627513, PMID 12721664, PMID 14603333, PMID 14669295, PMID 14673054, PMID 15297412
P30CA033572 (21), P30CA015704 (15), 2018 (12), 2023 (7), U10CA180821 (7), 2016 (6), 2025 (6), U10CA180888 (6), UM1CA186689 (6), UM1CA186712 (6), 2014 (5), 2015 (5), P01CA078902 (5), P30CA016672 (5), U10CA031946 (5)